Duration of luteal phase support with progesterone pessaries to improve the success rate in assisted reproduction cycles. A prospective randomised control trial. - DOLS

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-000599-33-GB

Enrollment

460

Registered

2006-06-11

Start date

2006-08-21

Completion date

Unknown

Last updated

2019-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Women undergoing assisted conception

Interventions

Product Name: cyclogest 400mg Pharmaceutical Form: Pessary INN or Proposed INN: progesterone PhEur Concentration unit: mg milligram(s) C

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Biochemical pregnancy 2 weeks after embryo transfer using a urinary pregnancy test. Progesterone treatment (2 weeks) completed upto day of pregnancy test. Fresh embryo IVF/ICSI cycle. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Frozen embryo transfer

Design outcomes

Primary

Measure	Time frame
Main Objective: To determine if an extra 10 weeks of progesterone (to make 12 weeks), after embryo implantation, increases the successful clinical pregnancy rate in assisted conception;Secondary Objective: ; Primary end point(s): Viable pregnancy at 14 weeks on ultrasound scan. (At end of period taking pessaries). Live birth.	—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026